XtremisBio Overview
- Status
-
Private
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
1
XtremisBio General Information
Description
Developer of targeted RAS (rat sarcoma) cancer therapy designed to treat advanced cancers driven by KRAS (Kirsten rat sarcoma viral oncogene homolog) mutations using a downregulation mechanism. The company offers a proprietary drug focused on disrupting RAS signaling pathways to selectively kill cancer cells, enabling healthcare providers to overcome treatment resistance and improve outcomes for patients with hard-to-treat tumors.
Contact Information
Website
www.xtremisbio.comCorporate Office
- Seattle, WA
- United States
Corporate Office
- Seattle, WA
- United States
XtremisBio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Accelerator/Incubator | Completed | Startup |
XtremisBio Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 3rdEyeBio | Accelerator/Incubator | Minority |
XtremisBio FAQs
-
Where is XtremisBio headquartered?
XtremisBio is headquartered in Seattle, WA.
-
What industry is XtremisBio in?
XtremisBio’s primary industry is Drug Discovery.
-
Is XtremisBio a private or public company?
XtremisBio is a Private company.
-
What is XtremisBio’s current revenue?
The current revenue for XtremisBio is .
-
Who are XtremisBio’s investors?
3rdEyeBio has invested in XtremisBio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process